Shots:

• The EC approval follows CHMP’s positive recommendation for Yuflyma (high concentration formulation) granted in Dec'2020. The approval covers all 13 intended indications to treat multiple chronic inflammatory diseases
• The approval is based on analytical- pre/ clinical studies- demonstrating that Yuflyma is comparable to the reference product- in terms of safety- efficacy- PK/PD- and immunogenicity up to 24wks. and 1yr following treatment
• The company will take ECDRP to minimize lead time to launch the product in the UK and remains committed to delivering innovative and affordable medications

 ­ Ref: Businesswire | Image: Celltrion